Financial insights of AGIO

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	0	19,967	12,880	12,455
Cost of sales	1,319	1,879	1,679	1,702
Research and development	81,148	88,056	86,796	91,940
Selling, general and administrative	48,304	51,610	41,274	45,869
Total operating expenses	130,771	141,545	129,749	139,511
Loss from operations	-110,025	-121,578	-116,869	-127,056
Milestone payment from gain on sale of oncology business	0	0*	0	-
Gain on sale of contingent payments	0	0*	0	-
Interest income, net	10,795	12,410	13,369	14,513
Other income, net	119	113	67	523
Net (loss) income before taxes	0	-109,055*	-103,433	-
Income tax expense	0	-1,016*	0	-
Net (loss) income	-99,111	-108,039	-103,433	-112,020

Basic EPS	-1.69	-1.851	-1.78	-1.93
Diluted EPS	-1.69	-1.851	-1.78	-1.93
Basic Average Shares	58,782,241	58,356,968	58,139,277	57,932,576
Diluted Average Shares	58,782,241	58,356,968	58,139,277	57,932,576

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.